Business Context and Reporting Period
Company: REGENXBIO Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 1, 2023
Event: Entry into an "At-the-Market" (ATM) Equity Offering Sales Agreement with BofA Securities, Inc.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure of a financing arrangement rather than a financial performance report.
- Maximum Offering Size: Up to $150.0 million in aggregate offering price.
- Security Type: Common Stock, par value $0.0001 per share.
- Agent Commission: Up to 3% of the aggregate gross sales price of shares sold.
Material Changes
The material change disclosed is the establishment of a new mechanism to sell equity. The Company entered into a Sales Agreement allowing it to offer and sell shares from time to time through an "at the market offering" on the Nasdaq Global Select Market or otherwise at prevailing market prices. The Company retains the right to establish parameters for sales, including minimum prices, and is not obligated to sell any shares.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the Company may enter into a separate terms agreement to sell shares directly to the Agent as principal in a firm commitment underwritten offering. The agreement may be terminated by either party at any time with written notice.
Risks and Contingencies:
- Sales are subject to market conditions and the Company's discretion regarding pricing and timing.
- The Agent and its affiliates provide other financial services to the Company for which they receive customary fees.
- The Sales Agreement contains customary representations, warranties, and indemnification rights.
Investor Verification Checklist
- Verify the current share price and trading volume on the Nasdaq Global Select Market to assess potential dilution impact.
- Review the Company's most recent 10-Q or 10-K for actual cash position and burn rate to understand the necessity of this capital raise.
- Monitor future prospectus supplements for specific details on the number of shares sold and proceeds received.
- Check for any subsequent filings indicating the termination of the Sales Agreement or the execution of a firm commitment underwriting.